Introduction
Multiple myeloma (MM) is a clonal B-cell neoplasm in which the malignant tumor cells are localized to the bone marrow. Within the bone marrow, the neoplastic cells lie in close proximity to stromal cells, which provide signals required for their progression through different disease stages. 1 These signals include a variety of cytokines and growth factors, stimulating tumor growth and survival. Several of these soluble mediators have the potential to bind to heparin, a glycosaminoglycan (GAG) structurally related to heparan sulfate (HS), suggesting that heparan sulfate proteoglycans (HSPGs), expressed on the cell surface of MM cells or in the extracellular matrix of the bone marrow, might modulate their function.
HSPGs are proteins that are covalently linked to sulfated GAG chains composed of alternating glucuronic acid and N-acetylglucosamine units. 2, 3 These molecules, which are widespread throughout mammalian tissues as extracellular matrix components and membrane-bound molecules, have been implicated in several important biologic processes, including cell adhesion and migration, tissue morphogenesis, angiogenesis, and regulation of blood coagulation. In these processes, HSPGs are believed to function as scaffold structures, designed to accommodate proteins through noncovalent binding to their GAG chains. Their ligand-binding sites reside within discrete sulfated domains formed by complex, cell-specific, chemical modifications of the HS disaccharide repeat. 2, 4 Binding of proteins, including growth factors and cytokines, to HS may serve a variety of functions, ranging from immobilization and concentration to distinct modulation of biologic function. This functional importance is illustrated by fibroblast growth factor 2 in which binding to its signal-transducing receptors and consequent biologic effects are critically dependent on its interaction with cell surface HSPGs. 5, 6 Recently, genetic studies have provided compelling evidence for an in vivo role of cell surface HSPGs in growth control and morphogenesis in Drosophila, mice, and humans. 7 Syndecan-1 is a member of a family of 4 mammalian HSPGs expressed in a cell-and tissue-specific pattern. 3 It is highly expressed on many epithelia where it contributes to cell adhesion and epithelial morphogenesis. 3 Moreover, by stimulating the activity of the oncoprotein Wnt-1, it can promote the development of mouse mammary gland tumors. 8 Within the immune system, syndecan-1 is expressed on terminally differentiated B cells, ie, plasma cells, and on their malignant counterpart, MM. 9, 10 Furthermore, it is present on a subset of AIDS-related non-Hodgkin lymphomas, including primary effusion lymphoma (PEL). 11 The biologic function of syndecan-1 in normal and neoplastic B cells is as yet incompletely understood. Syndecan-1 in lymphoblastoid B cells or MM cells was reported to promote cell adhesion and spreading on matrix molecules like type I collagen and to mediate homotypic cell aggregation. 12, 13 Recently, syndecan-1 has been shown to colocalize with growth factors in the uropods of MM cells, 14 but so far there is no direct evidence that it regulates their biologic activity. Here, we have explored the role of syndecan-1 in growth factor signaling. We show that syndecan-1 on MM cells binds hepatocyte growth factor/scatter factor (HGF), a multifunctional cytokine that regulates integrin-dependent adhesion and migration of B cells and is a putative regulator of tumor growth in both MM and PEL. [15] [16] [17] Importantly, syndecan-1 strongly promotes HGF-induced signaling through Met, the receptor tyrosine kinase for HGF, resulting in enhanced activation of signaling pathways involved in the control of cell proliferation and survival.
Materials and methods

Antibodies
Mouse monoclonal antibodies (mAbs) used were anti-syndecan-1 (CD138, clone B-B4, immunoglobulin G1 [IgG1]; Coulter Immunotech, Marseille, France); anti-syndecan-2, 10H4 (IgG1); anti-syndecan-4, 8G3 (IgG1); anti-glypican-1, S1 (IgG1) (all kindly provided by Dr G. David, Center for Human Genetics, University of Leuven, Leuven, Belgium); anti-HGF, 24 612.111 (IgG1; R&D Systems, Abington, United Kingdom); antiheparan sulfate, 10E4 (IgM; Seikagaku, Tokyo, Japan), anti-desaturated uronate from heparitinase-treated heparan sulfate (⌬HS stub), 3G10 
Cell lines, primary myeloma cells, and transfectants
MM cell line XG-1 was described elsewhere. 18 LME-1 was isolated from a patient with MM at the Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands. MM cell lines were cultured in Iscoves medium (Gibco BRL/Life Technologies, Breda, The Netherlands) containing 10% fetal calf serum (Integro, Zaandam, The Netherlands), 100 IU/mL penicillin, and 100 IU/mL streptomycin (Life Technologies), 20 g/mL human recombinant transferrin (Sigma, Bornem, Belgium), 50 M ␤-mercapto ethanol, and 500 pg/mL interleukin 6 (IL-6) (R&D Systems). Primary myeloma (PM) cells were obtained from the pleural effusion of a patient with MM. Mononuclear cells were harvested by standard FicollPaque density gradient centrifugation (Amersham Pharmacia, Uppsala, Sweden) and kept on a stromal cell feeder-layer in Iscoves medium (Gibco BRL/Life Technologies) containing 10% fetal calf serum (Integro), 100 IU/mL penicillin, and 100 IU/mL streptomycin (Life Technologies). For signaling experiments, primary tumor cells (containing more than 97% plasma cells) were serum starved for 24 hours in the presence of 2% fetal calf serum, after which the cells were kept under serum-free conditions for 3 hours. The Burkitt lymphoma cell line Namalwa was purchased from American Type Culture Collection (ATCC, Rockville, MD). The Mettransfected Namalwa (Nam MET ) was described previously. 19 Syndecan-1-and glypican-1-transfected Namalwa cells (Nam SYN and Nam GLYP ) were obtained by electroporation by using the eukaryotic expression vector pCDNA3 containing the full-length human syndecan-1 complementary DNA or glypican-1 complementary DNA (kindly provided by Dr G. David). Transfectants were selected in medium containing 1.6 mg/mL neomycin (Sigma). Syndecan-1-and glypican-1-positive cells were subcloned by using a FACStar flow cytometer (Becton Dickinson, Mountain View, CA). Namalwa cells were cultured in RPMI 1640 (Life Technologies) supplemented with 10% Fetal Clone I serum (HyClone Laboratories, Logan, UT), 10% fetal calf serum (Integro), 2 mM L-glutamine, 100 IU/mL penicillin, and 100 IU/mL streptomycin (all Life Technologies).
Enzyme treatments
For enzymatic cleavage of HS, cells were treated with either 10 mU/mL heparitinase (Flavobacterium heparinum, EC 4.2.2.8; ICN Biomedicals, Aurora, OH) or, as control, 50 mU/mL chondroitinase ABC (Proteus vulgaris, EC 4.2.2.4; Boehringer Mannheim, Almere, The Netherlands). The cleavage of HS by heparitinase was determined by the loss of cell surface-expressed HS (mAb 10E4) and the simultaneous gain of HS-stub expression (mAb 3G10).
Flow-activated cell sorter analysis
Flow-activated cell sorter (FACS) analyses using a single staining technique were described previously. 20 For binding of recombinant human HGF (R&D Systems) or mutant HP1, 21 cells were incubated with saturating concentrations for 1 hour at 4°C before the antibody incubations. Washing with FACS buffer followed this step.
Immunoprecipitation and Western blot analysis
Immunoprecipitation and Western blotting were performed as described. 20 For analysis of phosphorylation of PKB/Akt and the MAP kinases extracellular signal-related kinase (Erk)1 and Erk2, after the indicated treatments, 3 ϫ 10 5 cells were directly lysed in sample buffer, separated by 10% sodium dodecylsulfate-polyacrylamide gel electrophoresis, and blotted. Equal loading was confirmed by Ponceau S staining of the blot. The part of the blot above 130 kd was stained with anti-Met (C12), the middle part (50 to 130 kd) was stained with antiphospho PKB/Akt, and the bottom part (below 50 kd) was stained with antiphospho MAP kinase antiserum (all from New England Biolabs). Primary antibodies were detected by HRPconjugated goat antirabbit or HRP-conjugated rabbit antimouse.
Cell proliferation assay
Cells were plated in 96-well flat-bottom tissue culture plates (Costar, Cambridge, MA) at a density of approximately 100 000 cells/mL (200 L per well) in the absence of IL-6 and serum, in supplemented Iscoves medium as described above. HGF was added, and cells were cultured for 7 days. Cell numbers and viability were determined by adding propidium iodide and analysis on a FACScalibur (Becton Dickinson). For proliferation, the cultures were pulsed with 0.0185 MBq (0.5 Ci) (methyl- 
Results
Expression of HS moieties and proteoglycan core proteins on MM cells
Expression of the HSPG syndecan-1 as well as Met, the receptor tyrosine kinase for HGF, is common on MM cells. 10, 22 This expression suggests that HGF might not only interact with Met but also with syndecan-1, resulting in a ternary interaction between Met, HGF, and syndecan-1 at the MM cell surface. This ménage a trois might promote tumorigenesis. To explore this hypothesis, we used 2 MM cell lines, ie, XG-1 18 and LME-1, as well as primary tumor cells from a patient with MM patient (PM). FACS analysis demonstrated that these cells express high levels of both HS and syndecan-1 ( Figure 1 ) but lack expression of other proteoglycan core proteins, including other syndecans, glypican-1, and CD44v3 (data not shown). In accordance with these FACS data, a single HSPG of approximately 90 kd was detected by immunoblotting in the cell lysates of XG-1, LME-1, and PM cells ( Figure 1C , left panel). A HSPG of similar size was also present in the lysates of syndecan-1-transfected Namalwa Burkitt lymphoma cells (Nam SYN ), but not in that of untransfected (Nam) or glypican-1 (Nam GLYP )-transfected cells ( Figure 1C, left panel) . Stripping and restaining the blot with an antisyndecan-1 mAb confirmed that this 90-kd HSPG represents syndecan-1 ( Figure 1C , right panel), indicating that syndecan-1 is the major, and presumably only, HSPG expressed by XG-1, LME-1, and PM cells studied.
Stimulation of MM cells with HGF leads to activation of the phosphatidylinositol 3-kinase/PKB and RAS/MAP kinase pathways as well as cell proliferation
In addition to expressing syndecan-1, the XG-1, LME-1, and PM cells express Met and possess a functional Met signaling pathway (Figure 2) . Stimulation of XG-1 and LME-1 with HGF resulted in a rapid tyrosine phosphorylation of Met (Figure 2A ) as well as phosphorylation of PKB/Akt and the MAP kinases Erk1 and Erk2 ( Figure 2B ). In the PM cells we also observed a strong HGFinduced serine phosphorylation of PKB/Akt, whereas the phosphorylation of MAP kinases Erk1 and Erk2 increased approximately 2-fold ( Figure 2B ). Hence, signaling by Met in these MM cells leads to activation of phosphatidylinositol 3-kinase (PI3-K)/PKB as well as RAS/MAP kinase pathways, signaling routes that have been implicated in the regulation of cell survival and proliferation, 
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Syndecan-1 binds HGF by its HS moieties and promotes signaling through Met
We subsequently investigated the ability of syndecan-1 to interact with HGF. The MM cell lines XG-1 and LME-1, the PM cells, as well as syndecan-1-transfected Namalwa (Nam SYN) cells were found to bind high levels of HGF (Figure 4) , whereas wild-type Namalwa cells bound virtually no HGF. Importantly, this HGF binding was largely dependent on HS moieties decorating syndecan-1 and heparitinase but not chondroitinase ABC; pretreatment of the cells resulted in a strongly reduced HGF binding (Figure 4) . Moreover, HP-1, a mutant form of HGF with a more than 50-fold decreased affinity for HS, 21 showed only a weak binding to the MM cells and Nam SYN (Figure 4) .
To explore the functional consequence of the HGF and syndecan-1 interaction, we studied HGF/Met signaling in XG-1 and PM cells from which the HS moieties had been removed by heparitinase treatment. As shown in Figure 5A , removal of HS from XG-1 resulted in a strongly reduced tyrosine phosphorylation of Met in response to HGF. Apart from the autophosphorylation of Met, the HGF-induced activation of downstream effector molecules of the HGF/Met signaling pathway, indicative for the antiapoptotic and proliferative effects of HGF, ie, the kinase PKB/Akt, as well as the MAP kinases Erk1 and Erk2, was greatly inhibited by the removal of HS from both XG-1 ( Figure 5B) . In PM cells, the HGF-induced activation of the kinase PKB/Akt was also completely inhibited as a result of the removal of HS ( Figure 5C ). Because of the high baseline HGF-independent activity of the MAP kinases Erk1 and Erk2 in PM cells, removal of the HS moieties hardly reduced the phosphorylation of the MAP kinases Erk1 and Erk2 ( Figure 5C ). Importantly, the reduction in PKB/Akt and/or MAP kinase activation in XG-1 and PM cells did not result from nonspecific effects of the heparitinase treatment, as their activation by insulin, which does not bind to HS, was unaffected ( Figure 5B and C) .
Discussion
Recently, biochemical, cell biologic, and genetic studies have converged to reveal that integral membrane HSPGs are critical regulators of growth and differentiation of epithelial and connective tissues. By immobilizing and oligomerizing cytokines and by presenting them to their high affinity receptors, HSPGs create niches in the microenvironment and regulate cytokine responses. Because a vast number of cytokines and growth factors involved in the growth and differentiation of normal and neoplastic lymphocytes contain potential HS binding sites, HSPGs presumably also play important roles in the immune response and in the development and progression of lymphoid tumors. However, the expression and function of HSPGs on the cell surface of normal and neoplastic lymphocytes has thus far remained largely unexplored. In the present study, we investigated the expression and function of HSPGs on MM cell lines and primary MM tumor cells. We demonstrate that the HSPG syndecan-1 on MM cells is capable of binding HGF. This interaction promotes signaling through Met, the receptor tyrosine kinase for HGF, and regulates the activity of signaling pathways that control cell proliferation and survival.
Our findings present the first direct evidence that syndecan-1 regulates growth factor signaling in MM. Cell surface-expressed syndecan-1 presumably acts by increasing the effective concentration of HGF on the plasma membrane, an effect that may be modulated by soluble syndecan-1 shed from the MM cell surface, 26 whereas the binding of several HGF molecules to syndecan-1 may promote dimerization and oligomerization of Met, leading to enhanced receptor activation ( Figure 6 ). Alternatively, by inducing a conformational change, syndecan-1 might influence the affinity of HGF for Met, as has been demonstrated for HSPG binding of the NK1 splice variant of HGF. 27 Furthermore, the polarized distribution of syndecan-1, as observed on myeloma cells, 14 may impose a constraint on the spatial distribution of HGF, resulting in the clustering of activated Met and Met-associated signaling molecules ( Figure 6 ). In this scenario, the potentiation of Met signaling may be partially explained by HGF-mediated colocalization of syndecan-1 and Met, which may bring relevant intracellular signaling molecules in the proximity of each other. Indeed, several syndecan family members have been reported to associate with signaling molecules by means of their cytoplasmic tails. Syndecan-4, for example, can interact with (and activate) protein kinase C-␣, PIP2, and Syndesmos, which are all implicated in syndecan-4-controlled integrin-mediated focal adhesion formation and cell spreading. 28 Furthermore, all syndecans contain a motive through which they can interact with the guanylate kinase CASK/LIN-2, 28 affecting its nuclear translocation and transcription regulatory activity. 29 Interestingly, our data establish a functional link between syndecan-1 and the HGF/Met pathway, a signaling route that induces complex biologic responses in target cells, including motility, growth, and morphogenesis. In mice, met or hgf deficiency results in embryonic death with severe defects in the development of the placenta, liver, and limb muscles, whereas uncontrolled activation of Met, in both mice and humans, has been implicated in tumor growth, invasion, and metastasis (reviewed in van der Voort et al 15 ) . Of note, studies in hereditary papillary renal carcinoma established a causative role for Met mutations in human cancer. 30 These mutations result in enhanced kinase activity on stimulation with HGF and were shown to mediate transformation, invasive growth, and protection from apoptosis. 31 The HGF/Met pathway has also been implicated in B-cell development and neoplasia. 15, 16, 19 During normal B-cell differentiation, Met is expressed at the GC and plasma cell stage, whereas HGF is produced by follicular dendritic cells 19 and by bone marrow stromal cells. 32 HGF stimulation of B lymphocytes leads to enhanced integrin activity, promoting cell adhesion to VCAM-1, a major integrin ligand on follicular dendritic cells as well as B-cell migration. 19, 33 Interestingly, in GC cells, presentation of HGF by the HSPG CD44v3 promotes Met signaling. 15 In B-cell malignancies, the HGF/Met pathway may promote tumorigenesis through both autocrine and paracrine mechanisms. In PEL, 17 as well as MM, Met and HGF are often coexpressed, suggesting autocrine stimulation. 16 Because bone marrow stromal cells have been reported to produce HGF, 32 paracrine stimulation of MM cells may also take place within the bone marrow microenvironment. Consistent with a role for the HGF/Met in MM progression, high serum levels of HGF were reported to be associated with unfavorable prognosis in patients with MM. 34 The biologic processes controlled by the HGF/Met pathway in MM cells are as yet incompletely defined. Our current study demonstrates that HGF can promote tumor growth (Figure 3 ), a function presumably involving transcription regulatory signals delivered through the activated RAS/MAP kinase pathway ( Figure  2B ). In addition, HGF stimulation might also affect tumor dissemination and/or tumor cell survival. A role in MM dissemination is suggested by the fact that HGF has been shown to regulate integrin activity on GC B cells and promotes adhesion and migration of Burkitt lymphoma cell lines. 19, 33, 35 Key regulatory molecules implicated in inside-out signaling to integrins are PI3-K and different RAS-like guanosine triphosphatases, the activity of which can be controlled by HGF/Met. 36 In MM cell survival, the HGF/Met pathway may also play a critical part. Studies in several cell types, including liver cell precursors and carcinoma cells, have indicated that the HGF/Met pathway can generate potent survival signals. 37 Antiapoptotic signals in MM might be transduced through the PI3-K/PKB pathway, which was activated by HGF in our MM cell lines and primary tumor cells ( Figure 2B ). PKB/Akt is able to phosphorylate BAD, a BCL-2 antagonist expressed in B cells, and may thereby suppress the proapoptotic effects of BAD. 23 In conclusion, our present findings demonstrate that syndecan-1 strongly promotes HGF/Met signaling, resulting in enhanced activation of signaling pathways involved in the control of cell proliferation and survival. Clearly, this regulatory role of syndecan-1 may not be limited to the HGF/Met pathway but may extend to other pathways driven by heparin-binding growth factors like heparin-binding epidermal growth factor and fibroblast growth factor 2, outlining an important role for syndecan-1 in the pathogenesis of MM. 
